tradingkey.logo

Sol Gel Technologies Ltd

SLGL

5.090USD

+0.669+15.16%
Market hours ETQuotes delayed by 15 min
141.80MMarket Cap
LossP/E TTM

Sol Gel Technologies Ltd

5.090

+0.669+15.16%
More Details of Sol Gel Technologies Ltd Company
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Company Info
Company codeSLGL
Company nameSol Gel Technologies Ltd
IPO dateFeb 01, 2018
Founded at1997
CEO- -
Number of employees34
Security typeOrdinary Share
Fiscal year-endFeb 01
AddressGolda Meir 7
CityNESS-ZIONA
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code- -
Phone97289313433
Websitehttp://www.sol-gel.com
Company codeSLGL
IPO dateFeb 01, 2018
Founded at1997
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
38.13K
+343.42%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
38.13K
+343.42%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, May 4
Update time: Sun, May 4
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
M.Arkin Dermatology, Ltd.
64.86%
Phoenix Investment and Finances Ltd
8.87%
Migdal Insurance and Financial Holdings Ltd
4.41%
Harel Insurance Investments and Financial Services Ltd
3.30%
Arkin (Moshe)
1.37%
Other
17.19%
Shareholder Statistics
Shareholder
Proportion
M.Arkin Dermatology, Ltd.
64.86%
Phoenix Investment and Finances Ltd
8.87%
Migdal Insurance and Financial Holdings Ltd
4.41%
Harel Insurance Investments and Financial Services Ltd
3.30%
Arkin (Moshe)
1.37%
Other
17.19%
Type
Shareholder
Proportion
Corporation
64.86%
Investment Advisor
13.44%
Insurance Company
4.68%
Individual Investor
1.37%
Research Firm
0.60%
Investment Advisor/Hedge Fund
0.05%
Other
15.00%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
35
2.45M
67.44%
+70.65K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
2023Q2
29
22.04M
83.43%
-335.52K
2023Q1
32
22.23M
86.47%
+2.20M
2022Q4
34
20.25M
87.57%
+14.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
M.Arkin Dermatology, Ltd.
18.07M
64.86%
+2.00M
+12.45%
Apr 03, 2024
Phoenix Investment and Finances Ltd
2.47M
8.87%
--
--
Dec 31, 2024
Migdal Insurance and Financial Holdings Ltd
1.23M
4.41%
--
--
Dec 31, 2024
Harel Insurance Investments and Financial Services Ltd
920.33K
3.3%
--
--
Dec 31, 2024
Arkin (Moshe)
86.00K
0.31%
--
--
Apr 03, 2024
Yelin Lapidot Provident Funds Management Ltd
227.08K
0.82%
-2.10K
-0.92%
Dec 31, 2024
Morgan Stanley & Co. LLC
88.24K
0.32%
+54.88K
+164.51%
Dec 31, 2024
Menora Mivtachim Insurance Ltd.
76.11K
0.27%
--
--
Dec 31, 2024
BNP Paribas Securities Corp. North America
39.50K
0.14%
+1.80K
+4.77%
Dec 31, 2024
View more
Related ETFs
Update time: 7 hours ago
Update time: 7 hours ago
Name
Proportion
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data